INOVIO uses proprietary technology to design DNA plasmids — small circular DNA molecules that work like software that the body’s cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® delivery devices help ensure our DNA medicines enter the body’s cells for optimal effect, without chemical adjuvants or nanoparticles and without the risk of anti-vector response seen with viral vector platforms.
Over 15,000 doses of DNA medicines have been administered using our proprietary CELLECTRA devices to more than 5,000 patients in various clinical trials, and the data is compelling: a growing body of research indicates that DNA medicines offer many potential advantages and are generally well-tolerated, versatile, immunogenic and scalable.
© Copyright 2024 INOVIO Pharmaceuticals. All rights reserved.